Recs

0

Eli Lilly: If at First You Don't Succeed...

By | More Articles
December 14, 2012 | Comments (0)

Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, Merck (NYSE: MRK  ) gave us an update on its Alzheimer's program last week, and now, Eli Lilly (NYSE: LLY  ) has given an update on its Alzheimer's drug solanezumab. The company plans to conduct further phase 3 trials for patients with a milder form of the disease, despite failures with the drug in other phase 3 trials, as the data suggests there may be some benefit for those patients.

Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Elan and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2155515, ~/Articles/ArticleHandler.aspx, 5/23/2013 12:08:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
DOW 15,307.17 -80.41 -0.52%
S&P 500 1,655.35 -13.81 -0.83%
NASD 3,463.30 -38.82 -1.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/22/2013 4:00 PM
MRK $46.71 Down -0.62 -1.31%
Merck & Co., Inc. CAPS Rating: ****
PFE $29.30 Up +0.52 +1.81%
Pfizer CAPS Rating: ****
LLY $54.92 Down -0.22 -0.40%
Eli Lilly & Co. CAPS Rating: ****
ELN $12.04 Down -0.03 -0.25%
Elan CAPS Rating: ***
JNJ $88.46 Down -0.13 -0.15%
Johnson & Johnson CAPS Rating: *****

Advertisement